Aldeyra Therapeutics Inc

ALDX

5.530USD

+0.440+8.64%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Aldeyra Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

84 / 392

Overall Ranking

210 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Aldeyra Therapeutics Inc Highlights

StrengthsRisks

Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.

Undervalued

The company’s latest PE is -7.66, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 39.75M shares, decreasing 0.09% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 90.01K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.24.

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

9.667

Target Price

+89.91%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Aldeyra Therapeutics Inc is 7.15, ranking 146 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.15

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.96

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Aldeyra Therapeutics Inc is 6.20, ranking 314 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -7.66, which is -80.87% below the recent high of -1.47 and -49.25% above the recent low of -11.44.

Score

Industry at a Glance

Previous score

6.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 84/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Aldeyra Therapeutics Inc is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 9.50, with a high of 13.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

9.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Aldeyra Therapeutics Inc is 8.99, ranking 45 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.33 and the support level at 4.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.34

Change

1.65

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Aldeyra Therapeutics Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 62.22%, representing a quarter-over-quarter decrease of 7.73%. The largest institutional shareholder is The Vanguard, holding a total of 3.70M shares, representing 6.15% of shares outstanding, with 0.96% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Knoll Capital Management, LLC

5.48M

--

Perceptive Advisors LLC

5.22M

+28.89%

The Vanguard Group, Inc.

Star Investors

3.59M

+2.58%

BlackRock Institutional Trust Company, N.A.

3.50M

-1.20%

Ardsley Advisory Partners LP

1.90M

-7.32%

AQR Capital Management, LLC

1.51M

+2.14%

Brady (Todd C)

1.42M

+23.16%

D. E. Shaw & Co., L.P.

1.38M

+182.94%

Kingdon Capital Management, L.L.C.

1.33M

--

Geode Capital Management, L.L.C.

1.18M

+2.60%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Aldeyra Therapeutics Inc. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Aldeyra Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Aldeyra Therapeutics Inc

ALDX

6.82 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment